Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides a source of calories and fluid for intravenous administration. It increases blood glucose levels and may cause diuresis via osmotic effects. Sodium chloride provides electrolyte replacement to maintain or restore intravascular volume and extracellular fluid balance.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
FDA: Parenteral source of calories and fluid in patients requiring IV hydration; treatment of hypovolemia; prevention or correction of dehydration and electrolyte imbalances.,Off-label: Adjunctive therapy in the management of hyperkalemia (with insulin); treatment of hypoglycemia.
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous infusion; typical adult dose is 100-200 m L/hour of D5 0.9% Na Cl, adjusted based on fluid and electrolyte status, glucose monitoring, and clinical indication.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Glucose: ~1.5–2 hours for metabolic clearance in euglycemic individuals; prolonged in renal impairment (adds renal excretion of glucose if threshold exceeded). Dextrose solution constituents (water, sodium, chloride) have no true half-life; water turnover half-life ~3–4 hours in adults.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Dextrose is metabolized via glycolysis and the citric acid cycle in all tissues; insulin-dependent cellular uptake occurs in most cells. Sodium chloride is not metabolized but is excreted renally.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal elimination of free water and electrolytes. Glucose is metabolized to CO2 and water; excess glucose not metabolized is excreted renally as glucose (glucosuria) when renal threshold exceeded. Sodium and chloride are excreted renally, with >90% of filtered sodium reabsorbed; chloride follows sodium. No biliary or fecal elimination of intact drug.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Glucose: negligible binding (<1%). Sodium and chloride: not protein bound.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Glucose: Vd ~0.15–0.25 L/kg (total body water). Sodium: Vd ~0.25 L/kg (extracellular fluid). Chloride: Vd ~0.25–0.35 L/kg. Water distributes throughout total body water (~0.6 L/kg).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100% bioavailable. Not applicable to oral or other routes.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
In acute kidney injury or chronic kidney disease, use with caution; monitor for volume overload and hypernatremia. GFR < 30 m L/min: restrict volume to 500-1000 m L/day with careful sodium assessment. GFR 30-50 m L/min: use standard dosing with monitoring. GFR > 50 m L/min: no adjustment required.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific Child-Pugh based dose adjustments; monitor for fluid retention and electrolyte disturbances in decompensated cirrhosis (Child-Pugh B or C). Use with caution in ascites.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Weight-based infusion: neonates 0-28 days: 5-10 m L/hour; infants 1-12 months: 10-20 m L/hour; children 1-12 years: 20-50 m L/hour; adolescents 13-17 years: 50-100 m L/hour. Adjust based on glucose and electrolyte monitoring.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Elderly patients: start at lower infusion rates (50-100 m L/hour) and titrate; monitor for fluid overload, hyperglycemia, and hypernatremia due to reduced renal function and comorbid conditions. Adjust based on cardiac status and renal function.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
None.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Risk of fluid overload in patients with congestive heart failure, renal insufficiency, or hepatic cirrhosis.,Monitor serum glucose, electrolytes, and fluid balance; dextrose can cause hyperglycemia, especially in diabetic patients.,Do not administer simultaneously with blood through same tubing due to risk of RBC aggregation/hemolysis.,Intraosseous administration may cause compartment syndrome.,Use with caution in patients with preexisting electrolyte abnormalities or those receiving corticosteroids.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hyperglycemia with marked glycosuria or hyperosmolar coma.,Hypersensitivity to corn or corn products.,Severe electrolyte imbalances (e.g., hypernatremia) unless corrected.,Patients with anuria not related to hypovolemia.
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid high-sodium foods as this solution already contains sodium chloride. Diabetic patients should monitor carbohydrate intake, as dextrose provides 5 g/100 m L. No direct food interactions, but overall sodium and glucose intake should be considered.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Dextrose 5% in Sodium Chloride 0.9% is a crystalloid solution not associated with teratogenicity. No fetal risk has been identified in any trimester when used appropriately for fluid and electrolyte replacement. Maternal hyperglycemia or electrolyte disturbances may indirectly affect the fetus if improperly administered, but the solution itself is not teratogenic.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Both dextrose and sodium chloride are normal constituents of breast milk. Administration of this solution does not pose a risk to the nursing infant. The M/P ratio is not applicable as these substances are endogenous and not actively concentrated in milk.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy-related plasma volume expansion and increased glomerular filtration rate may require adjustments in infusion rate to avoid fluid overload or electrolyte imbalance. Dose should be individualized based on maternal fluid status, electrolyte levels, and renal function. No standard dose adjustment is necessary but careful titration is recommended.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Contains 5 g dextrose and 0.9 g sodium chloride per 100 m L; provides 170 kcal/L and 154 m Eq/L each of Na+ and Cl-. Monitor serum glucose in diabetic patients; avoid in hyperglycemia. Use with caution in heart failure, renal impairment, and hypertension due to sodium load. Incompatible with certain drugs (e.g., amphotericin B, erythromycin).
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This solution provides sugar and salt to replace fluids and energy.,Tell your doctor if you have diabetes, high blood pressure, or heart or kidney problems.,You may experience swelling due to the salt content; report shortness of breath or leg swelling.,Do not consume additional salty foods unless advised by your doctor.,Your blood sugar and electrolytes will be monitored during treatment.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides a source of calories and fluid for intravenous administration. It increases blood glucose levels and may cause diuresis via osmotic effects. Sodium chloride provides electrolyte replacement to maintain or restore intravascular volume and extracellular fluid balance.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 100-200 m L/hour of D5 0.9% Na Cl, adjusted based on fluid and electrolyte status, glucose monitoring, and clinical indication.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose 5% in Sodium Chloride 0.9% is a crystalloid solution not associated with teratogenicity. No fetal risk has been identified in any trimester when used appropriately for flu. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.